Provider Practices in Pulmonary Exacerbations of Cystic Fibrosis in the Era of Highly Effective Modulator Therapy
{{output}}
Rationale: Since the approval of elexacaftor/tezacaftor/ivacaftor (ETI), data suggests there have been changes in the management of pulmonary exacerbations (PEx) of Cystic Fibrosis (CF). ... ...
